Sort
21,281 grants matching “influenza”
Nonhuman Primate Core
$644,063Michael K Axthelm · Oregon Health & Science University · U54 · FY2010 · AI
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy
$644,035David Jay Burkhart · University Of Montana · R01 · FY2021 · AI
Discovery of SARS-CoV-2 antivirals using a replicon assay
$643,490Stefan G Sarafianos · Emory University · R01 · FY2023 · AI
Homeostasis and function of regulatory T cells in aging
$643,473Claire A Chougnet · Cincinnati Childrens Hosp Med Ctr · R56 · FY2019 · AG
Refinement of Very Low Leakage Non-Invasive Ventilation Mask for Infectious Patients
$643,238Daniel Micka · Creare, Llc · R44 · FY2024 · OH
Immunomodulation for Heart Allograft Tolerance
$643,226Richard N Pierson · University Of Maryland Baltimore · U01 · FY2015 · AI
Examining the Effects of Immulina to Increase Immune Resilience against Influenza Virus Infections
$643,143Gailen D. Marshall · University Of Mississippi · U19 · FY2024 · AT
Repertoire studies of human antibodies to RSV and MPV F
$643,125Theodore S Jardetzky · Stanford University · R01 · FY2018 · AI
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors
$643,028Matteo Porotto · Columbia University Health Sciences · R01 · FY2019 · AI
Immune Responses in Otitis Prone Children
$642,800Michael E Pichichero · Rochester General Hospital (Ny) · R01 · FY2015 · DC
COVID-19 Supplement: Systems Immune Profiling of Divergent Responses to Infection
$642,765David A. Hafler · Yale University · U19 · FY2021 · AI
Core D: Clinical Recruitment
$642,765Albert C Shaw · Yale University · U19 · FY2021 · AI
Investigating protective adaptive immune responses to influenza antigens using human tonsil organoids
$642,584Lisa Wagar · University Of California-Irvine · R01 · FY2023 · AI
Replication of influenza virus
$642,396Robert M Krug · University Of Texas At Austin · R01 · FY2008 · AI
Engineering Monodisperse Particulate Vaccines to Tailor Immunological Responses
$642,267Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U19 · FY2014 · AI
EID - Effects of avian migration & anthropogenic change on the distribution & tra
$642,156Thomas B Smith · University Of California Los Angeles · R01 · FY2008 · AI
Mechanisms of dysregulated immunity with aging
$642,138Daniel Robert Goldstein · University Of Michigan At Ann Arbor · R01 · FY2019 · AG
Protein therapy to treat virus induced cardiopulmonary injury
$642,124Jianjie Ma · University Of Virginia · R01 · FY2024 · HL
SWINE INFLUENZA VIRUS (SIV) IS ONE OF THE TOP RESPIRATORY INFECTIONS IN SWINE CAUSING SIGNIFICANT ECONOMIC LOSSES TO THE SWINE INDUSTRY EVERY YEAR. THE HIGH GENETIC DIVERSITY OF SIV AND THE CONSTANT EMERGENCE OF VARIANT VIRUSES THAT ARE ABLE TO ESCAPE IMMUNITY POSE SIGNIFICANT CHALLENGES TO VACCINE DEVELOPMENT. RECENTLY, STRATEGIES AIMING AT DEVELOPING BROADLY PROTECTIVE VACCINE CANDIDATES FOR HUMAN AND AVIAN INFLUENZA VIRUSESHAVE SHOWN PROMISSE. IN THE PRESENT PROJECT WE WILL ASSESS THE FESIBILITY AND EFFICACY OF TWO OF THESE STRATEGIES INVOLVING CONSENSUS AND CHIMERIC HA SEQUENCES AGAINST SWINE INFLUENZA. INITIALLY, WE WILL PERFORM A COMPARISON OF CONSENSUS HA VS CHIMERIC HA IN PIGS TO IDENTIFY WHICH PLATFORM HAS A BETTER CHANCE OF SUCCESS AGAINST SIV. THIS WILL BE FOLLOWED BY A FULL CHARACTERIZATION OF THE BEST PLATFORM, IN COMPARISON WITH A CURRENT WHOLE VIRUS INACTIVATED COMMERCIAL SIV VACCINE. WE EXPECT THAT THESE STUDIES WILL ALLOW US TO DETERMINE WHETHER THE CONSENSUS AND/OR CHIMERIC STRATEGIES WORK IN SWINE AGAINST SIV. ADDITIONALLY, WITH THE PROPOSED STUDIES WE EXPECT TO CHARACTERIZE IMMUNE RESPONSES THAT CORRELATE WITH CROSS-PROTECTIVE RESPONSES TO SIV IN PIGS.
$642,000Cornell University · · FY2022 · National Institute of Food and Agriculture
THE VAGINAL MICROBIOME, MATERNAL RESPONSE, AND PRETERM BIRTH
$641,981Molly Stout · Washington University · R01 · FY2019 · HD
Mechanistic studies of nucleic acid enzymes involved in DNA replication, transcription, and innate immunity
$641,967Smita S Patel · Rbhs-Robert Wood Johnson Medical School · R35 · FY2017 · GM
Regulation of T cell homeostasis and memory
$641,878Linda Mac Pherson Bradley · Trudeau Institute, Inc. · P01 · FY2009 · AI
The influence of evolutionary landscapes on protective antibody development
$641,818Timothy Andrew Whitehead · University Of Colorado · R01 · FY2019 · AI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases
$641,708Shawn Iadonato · Kineta, Inc. · N01 · FY2016 · AI
Proteomics Core
$641,561Nevan J Krogan · Icahn School Of Medicine At Mount Sinai · U19 · FY2014 · AI